CD30 as a Therapeutic Target for Lymphoma

@article{Schirrmann2013CD30AA,
  title={CD30 as a Therapeutic Target for Lymphoma},
  author={Thomas Schirrmann and Miriam Steinwand and Xenia Wezler and Andre ten Haaf and Mehmet Kemal Tur and Stefan Barth},
  journal={BioDrugs},
  year={2013},
  volume={28},
  pages={181-209}
}
Hodgkin’s lymphoma (HL) and ALK+ anaplastic large-cell lymphoma (ALCL) have become highly curable due to the success of modern regimens of chemotherapy and radiotherapy. However, up to one-third of the patients experience relapse or do not respond to first-line therapy, and half of them relapse again after secondary therapy with limited options for further treatment. In the last 15 years, monoclonal antibodies (mAbs) directed to surface receptors became a new and valuable therapeutic option in… CONTINUE READING
1
Twitter Mention

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies.

  • Expert opinion on investigational drugs
  • 2014
VIEW 15 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Anaplastic large cell lymphoma (ALCL) and breast implants: breaking down the evidence.

  • Mutation research. Reviews in mutation research
  • 2014
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 215 REFERENCES

Brentuximab Vedotin (SGN-35).

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2011
VIEW 31 EXCERPTS
HIGHLY INFLUENTIAL

Bispecific antibodies for cancer therapy.

  • Current opinion in drug discovery & development
  • 2009
VIEW 19 EXCERPTS
HIGHLY INFLUENTIAL

The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5.

  • FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 2004
VIEW 11 EXCERPTS
HIGHLY INFLUENTIAL

Radioimmunotherapy in follicular lymphoma.

  • Best practice & research. Clinical haematology
  • 2011
VIEW 16 EXCERPTS
HIGHLY INFLUENTIAL

Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma.

  • Biochemical pharmacology
  • 2010
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2010
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2009
VIEW 15 EXCERPTS
HIGHLY INFLUENTIAL